Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Director | May 05, 2020 | May 08, 2020 |
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
| Cocrystal Pharma, Inc.COCP · Entity 7621 | Director | January 09, 2026 | January 13, 2026 |
| EyePoint, Inc.EYPT · Entity 5702 | Director | January 02, 2026 | January 06, 2026 |
| PRECIGEN, INC.PGEN · Entity 4356 | Director | March 13, 2026 | March 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 05, 2020 · Filed May 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,191 |
Reported balance
After 2020-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 846 · Balance 9,191 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,879 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 29,879 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Cocrystal Pharma, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2036-01-09 | Direct | 16,410 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 16,410 · Balance 16,410 F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.
EyePoint, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2036-01-02 | Direct | 40,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000 |
PRECIGEN, INC.
Report date March 13, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,243,239 |
Reported balance
After 2026-03-13 transaction · row 1
1 source rowRow 1 · 2026-03-13 · Exercise / conversion · Acquired 71,839 · Balance 1,243,239 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-13 · Exercise / conversion · Disposed 71,839 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2: The RSUs vested in full on March 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
F2: The RSUs vested in full on March 13, 2026.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date November 03, 2009 · Filed November 04, 2009
Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 1
1 source rowRow 1 · 2009-11-03 · Disposition to issuer · Disposed 935,400 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.43 · Expires 2013-04-19 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2009-11-03 · Disposition to issuer · Disposed 900,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2009-11-03 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2009-11-03 · Disposition to issuer · Disposed 1,180,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2009-11-03 · Disposition to issuer · Disposed 1,100,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2009-11-03 · Disposition to issuer · Disposed 836,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2009-11-03 · Disposition to issuer · Disposed 868,300 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2014-02-22 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2009-11-03 · Disposition to issuer · Disposed 1,100,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Phantom Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2009-11-03 · Disposition to issuer · Disposed 196,761.57 · Balance 0 F4: Each unit of phantom stock is the economic equivalent of one share of common stock. F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F4: Each unit of phantom stock is the economic equivalent of one share of common stock.
F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.
Prometheus Biosciences, Inc.
Report date June 16, 2023 · Filed June 16, 2023
Section 16 reporting ended · disclosed 2023-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 1
1 source rowRow 1 · 2023-06-16 · Disposition to issuer · Disposed 2,123 · Balance 0 F1: Reflects restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.82 · Expires 2031-05-13 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-16 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.32 · Expires 2031-11-13 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-16 · Disposition to issuer · Disposed 541 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.02 · Expires 2032-05-18 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-16 · Disposition to issuer · Disposed 21,013 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units.
F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3)
F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
WARNER MEDIA, LLC
Report date June 14, 2018 · Filed June 18, 2018
Section 16 reporting ended · disclosed 2018-06-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Par Value $.01SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-06-14 transaction · row 1
1 source rowRow 1 · 2018-06-14 · Disposition to issuer · Disposed 49,089 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.39 · Expires 2019-10-28 | Direct | 0 |
Reported balance
After 2018-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-14 · Disposition to issuer · Disposed 4,019 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757). |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.84 · Expires 2020-05-21 | Direct | 0 |
Reported balance
After 2018-06-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-14 · Disposition to issuer · Disposed 5,708 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757). |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.81 · Expires 2022-05-15 | Direct | 0 |
Reported balance
After 2018-06-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-06-14 · Disposition to issuer · Disposed 5,336 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757). |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2021-05-20 | Direct | 0 |
Reported balance
After 2018-06-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-14 · Disposition to issuer · Disposed 4,880 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757). |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.84 · Expires 2024-06-13 | Direct | 0 |
Reported balance
After 2018-06-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-06-14 · Disposition to issuer · Disposed 2,898 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757). |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.83 · Expires 2023-05-23 | Direct | 0 |
Reported balance
After 2018-06-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-06-14 · Disposition to issuer · Disposed 2,996 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757). |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.37 · Expires 2026-06-17 | Direct | 0 |
Reported balance
After 2018-06-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-06-14 · Disposition to issuer · Disposed 3,108 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757). |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.00 · Expires 2025-06-19 | Direct | 0 |
Reported balance
After 2018-06-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-06-14 · Disposition to issuer · Disposed 2,460 · Balance 0 F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757). |
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Expires 2018-06-14 | IndirectBy Deferred Compensation Plan | 0 |
Reported balance
After 2018-06-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-06-14 · Disposition to issuer · Disposed 1,128.3387 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding phantom stock unit with respect to the Company's common stock acquired pursuant to the Time Warner Inc. Non-Employee Directors' Deferred Compensation Plan (the "Deferred Compensation Plan") was deemed converted into an amount in cash equal to approximately $100.8845 and reinvested in the investment option under the Deferred Compensation Plan that earns interest at a specified rate. Pursuant to the terms of the Deferred Compensation Plan, the amount credited to the account will be paid out in cash in a lump sum or in annual installments beginning on April 30, 2019. F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 14, 2018, AT&T Inc., a Delaware corporation ("AT&T"), acquired Time Warner Inc. (the "Company") pursuant to that certain Agreement and Plan of Merger, dated October 22, 2016, by and among the Company, AT&T, West Merger Sub, Inc., a wholly owned subsidiary of AT&T, and West Merger Sub II, LLC, a wholly owned subsidiary of AT&T (the "Merger Agreement"). The acquisition is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 9, 2017. In accordance with the terms of the Merger Agreement, each share of the Company's common stock was exchanged for 1.437 shares of AT&T common stock plus $53.75 in cash. Each disposition reported in this Form 4 is an exempt disposition.
F2: Pursuant to the Merger Agreement, each outstanding option to purchase the Company's common stock (a "Company Option"), whether vested or unvested, was converted into an option to acquire a number of shares of AT&T common stock equal to the number of shares of Company common stock under such Company Option, subject to the vesting and other terms in the applicable Company Option award agreement, except that the exercise price and the number of shares of AT&T common stock issuable upon exercise of such Company Option were adjusted based on the option exchange ratio determined under a formula in the Merger Agreement (which yields approximately 3.0757).
F3: Pursuant to the Merger Agreement, each outstanding phantom stock unit with respect to the Company's common stock acquired pursuant to the Time Warner Inc. Non-Employee Directors' Deferred Compensation Plan (the "Deferred Compensation Plan") was deemed converted into an amount in cash equal to approximately $100.8845 and reinvested in the investment option under the Deferred Compensation Plan that earns interest at a specified rate. Pursuant to the terms of the Deferred Compensation Plan, the amount credited to the account will be paid out in cash in a lump sum or in annual installments beginning on April 30, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerPhantom Stock Unit · Derivative | 196,761.57 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051069 · c91852_4x1.xml · derivative · entry 9 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 196,761.57 shares Expires not disclosed F4 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. F5 · price: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. F5 · derivative.exercise_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. F5 · derivative.expiration_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 868,300 | Not disclosed Strike: $22.91 | Not disclosed |
DisclosureSEC source: 0001209191-09-051069 · c91852_4x1.xml · derivative · entry 8 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 868,300 shares Expires 2016-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 836,000 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0001209191-09-051069 · c91852_4x1.xml · derivative · entry 7 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 836,000 shares Expires 2015-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 1,100,000 | Not disclosed Strike: $20.70 | Not disclosed |
DisclosureSEC source: 0001209191-09-051069 · c91852_4x1.xml · derivative · entry 6 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,100,000 shares Expires 2015-04-24 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 1,180,000 | Not disclosed Strike: $31.57 | Not disclosed |
DisclosureSEC source: 0001209191-09-051069 · c91852_4x1.xml · derivative · entry 5 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,180,000 shares Expires 2014-04-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (Right to Buy) · Derivative | 1,100,000 | Not disclosed Strike: $18.20 | Not disclosed |
DisclosureSEC source: 0001209191-09-051069 · c91852_4x1.xml · derivative · entry 4 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,100,000 shares Expires 2014-02-22 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 1,000,000 | Not disclosed Strike: $19.23 | Not disclosed |
DisclosureSEC source: 0001209191-09-051069 · c91852_4x1.xml · derivative · entry 3 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,000,000 shares Expires 2013-05-18 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerOption (right to buy) · Derivative | 900,000 | Not disclosed Strike: $17.43 | Not disclosed |
DisclosureSEC source: 0001209191-09-051069 · c91852_4x1.xml · derivative · entry 2 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 900,000 shares Expires 2013-04-19 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. Read SEC document |
| November 03, 2009 Filed Nov 4, 2009 22:53 UTC | Merck & Co., Inc. SGP · Entity 2807 | Disposition to issuerCommon Shares | 935,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-09-051069 · c91852_4x1.xml · nonDerivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Read SEC document |
| May 01, 2009 Filed May 5, 2009 18:00 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 868,300 | Not disclosed Strike: $22.91 | Not disclosed |
DisclosureSEC source: 0000310158-09-000049 · has727.xml · derivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868,300 Underlying: Common Shares · 868,300 shares Expires 2016-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2010, 2011 and 2012. The vesting of 173,660 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2009 year. Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 19:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionDeferred Stock Unit Award · Derivative | 200,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-09-000033 · has717.xml · derivative · entry 3 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 19:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | Tax withholdingCommon Shares | 92,700 | $23.70 | $2,196,990.00 |
DisclosureSEC source: 0000310158-09-000033 · has717.xml · nonDerivative · entry 2 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,400 Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 19:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-09-000033 · has717.xml · nonDerivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,028,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document |
| February 27, 2009 Filed Mar 3, 2009 22:11 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantPhantom Stock Unit · Derivative | 195,610 | $17.39 | $3,401,657.90 |
DisclosureSEC source: 0000310158-09-000010 · has708.xml · derivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,610 Underlying: Common Shares · 195,610 shares Expires not disclosed F1 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock. The units of phantom stock will be held in the Issuer's Phantom Stock Fund under the Issuer's non-qualified deferred compensation plan, and will become payable, in cash, following the reporting person's termination of service. F1 · derivative.exercise_date: Each unit of phantom stock is the economic equivalent of one share of common stock. The units of phantom stock will be held in the Issuer's Phantom Stock Fund under the Issuer's non-qualified deferred compensation plan, and will become payable, in cash, following the reporting person's termination of service. F1 · derivative.expiration_date: Each unit of phantom stock is the economic equivalent of one share of common stock. The units of phantom stock will be held in the Issuer's Phantom Stock Fund under the Issuer's non-qualified deferred compensation plan, and will become payable, in cash, following the reporting person's termination of service. Read SEC document |
| May 01, 2008 Filed May 5, 2008 20:46 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 836,000 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0000310158-08-000032 · has662.xml · derivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 836,000 Underlying: Common Shares · 836,000 shares Expires 2015-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2009, 2010 and 2011. The vesting of 167,200 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2008 year. Read SEC document |
| April 25, 2008 Filed Apr 29, 2008 19:51 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionDeferred Stock Unit Award · Derivative | 200,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-08-000016 · has658.xml · derivative · entry 3 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 25, 2008 Filed Apr 29, 2008 19:51 UTC | Merck & Co., Inc. SGP · Entity 2807 | Tax withholdingCommon Shares | 92,700 | $18.64 | $1,727,928.00 |
DisclosureSEC source: 0000310158-08-000016 · has658.xml · nonDerivative · entry 2 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,100 Read SEC document |
| April 25, 2008 Filed Apr 29, 2008 19:51 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-08-000016 · has658.xml · nonDerivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document |
| April 24, 2008 Filed Apr 24, 2008 16:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 7,400 | $18.29 | $135,346.00 |
DisclosureSEC source: 0000310158-08-000008 · has657.xml · nonDerivative · entry 9 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,800 Read SEC document |
| April 24, 2008 Filed Apr 24, 2008 16:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 11,470 | $18.28 | $209,671.60 |
DisclosureSEC source: 0000310158-08-000008 · has657.xml · nonDerivative · entry 8 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,400 Read SEC document |
| April 24, 2008 Filed Apr 24, 2008 16:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 50,730 | $18.27 | $926,837.10 |
DisclosureSEC source: 0000310158-08-000008 · has657.xml · nonDerivative · entry 7 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,930 Read SEC document |
| April 24, 2008 Filed Apr 24, 2008 16:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 15,800 | $18.26 | $288,508.00 |
DisclosureSEC source: 0000310158-08-000008 · has657.xml · nonDerivative · entry 6 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,200 Read SEC document |
| April 24, 2008 Filed Apr 24, 2008 16:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 4,600 | $18.25 | $83,950.00 |
DisclosureSEC source: 0000310158-08-000008 · has657.xml · nonDerivative · entry 5 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635,400 Read SEC document |
| April 24, 2008 Filed Apr 24, 2008 16:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 4,500 | $18.24 | $82,080.00 |
DisclosureSEC source: 0000310158-08-000008 · has657.xml · nonDerivative · entry 4 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,800 Read SEC document |
| April 24, 2008 Filed Apr 24, 2008 16:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 2,100 | $18.23 | $38,283.00 |
DisclosureSEC source: 0000310158-08-000008 · has657.xml · nonDerivative · entry 3 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,300 Read SEC document |
| April 24, 2008 Filed Apr 24, 2008 16:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 8,400 | $18.22 | $153,048.00 |
DisclosureSEC source: 0000310158-08-000008 · has657.xml · nonDerivative · entry 2 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,200 Read SEC document |
| April 24, 2008 Filed Apr 24, 2008 16:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 5,000 | $18.21 | $91,050.00 |
DisclosureSEC source: 0000310158-08-000008 · has657.xml · nonDerivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,800 Read SEC document |
| May 01, 2007 Filed May 3, 2007 14:13 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 1,180,000 | Not disclosed Strike: $31.57 | Not disclosed |
DisclosureSEC source: 0000310158-07-000026 · has607.xml · derivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,180,000 Underlying: Common Shares · 1,180,000 shares Expires 2014-04-30 F2 · price: Not Applicable. F1 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2006 Stock Incentive Plan and exercisable in one-third increments on May 1 of 2008, 2009 and 2010. The vesting of 236,000 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the 2007 year. Read SEC document |
| December 01, 2006 Filed Dec 5, 2006 01:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionDeferred Stock Unit Award · Derivative | 200,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-06-000142 · has577.xml · derivative · entry 3 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| December 01, 2006 Filed Dec 5, 2006 01:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | Tax withholdingCommon Shares | 92,700 | $21.93 | $2,032,911.00 |
DisclosureSEC source: 0000310158-06-000142 · has577.xml · nonDerivative · entry 2 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,800 Read SEC document |
| December 01, 2006 Filed Dec 5, 2006 01:20 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-06-000142 · has577.xml · nonDerivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document |
| May 19, 2006 Filed May 23, 2006 19:24 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 1,000,000 | Not disclosed Strike: $19.23 | Not disclosed |
DisclosureSEC source: 0000310158-06-000058 · has535.xml · derivative · entry 2 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Shares · 1,000,000 shares Expires 2013-05-18 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under Schering-Plough Corporation 2006 Stock Incentive Plan and exerciseable in one-third increments on April 1 of 2007, 2008 and 2009. The vesting of 200,000 option shares is subject to Schering-Plough's satisfaction of certain performance criteria for the year 2006. Read SEC document |
| May 19, 2006 Filed May 23, 2006 19:24 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantDeferred Stock Unit Award · Derivative | 200,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-06-000058 · has535.xml · derivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Shares · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under Schering-Plough Corporation 2006 Stock Incentive Plan. All of the shares become deliverable on April 1, 2009 subject to Schering-Plough's satisfaction of certain performance criteria for the year 2006. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 25, 2005 Filed Apr 27, 2005 19:47 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (right to buy) · Derivative | 1,100,000 | Not disclosed Strike: $20.70 | Not disclosed |
DisclosureSEC source: 0000310158-05-000020 · has476.xml · derivative · entry 2 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,000 Underlying: Common Shares · 1,100,000 shares Expires 2015-04-24 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan, exercisable in one-third increments on April 26 of each 2006, 2007 and 2008, subject to Schering-Plough's satisfaction of certain performance criteria for the year 2005 with respect to 220,000 option shares. Read SEC document |
| April 25, 2005 Filed Apr 27, 2005 19:47 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantDeferred Stock Unit Award · Derivative | 200,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-05-000020 · has476.xml · derivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan. All of the shares become deliverable on April 25, 2008, subject to Schering-Plough's satisfaction of certain performance criteria for the year 2005. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| February 23, 2004 Filed Feb 25, 2004 19:42 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantOption (Right to Buy) · Derivative | 1,100,000 | Not disclosed Strike: $18.20 | Not disclosed |
DisclosureSEC source: 0000310158-04-000041 · has362.xml · derivative · entry 3 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,000 Underlying: Common Shares · 1,100,000 shares Expires 2014-02-22 F6 · price: Not Applicable. F5 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan, exercisable in one-third increments on February 24 of each 2005, 2006 and 2007. Read SEC document |
| February 23, 2004 Filed Feb 25, 2004 19:42 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantDeferred Stock Unit Award · Derivative | 200,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-04-000041 · has362.xml · derivative · entry 2 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: Not Applicable. F4 · price: Not Applicable. F2 · derivative.exercise_date: Granted under the Schering-Plough Corporation 2002 Stock Incentive Plan. All of the shares become deliverable on February 23, 2007. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| February 23, 2004 Filed Feb 25, 2004 19:42 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantPhantom Stock Units · Derivative | 1,067,797 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-04-000041 · has362.xml · derivative · entry 1 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067,797 Underlying: Common Shares · 1,067,797 shares Expires not disclosed F7 · derivative.exercise_price: 1 for 1 F9 · price: Not Applicable. F8 · derivative.exercise_date: Includes grants under the Long-Term Performance Share Unit Incentive Plan and the Transformational Performance Contingent Shares Program. The shares of phantom stock become payable in cash upon the reporting person's termination of service as an employee of the Issuer. F8 · derivative.expiration_date: Includes grants under the Long-Term Performance Share Unit Incentive Plan and the Transformational Performance Contingent Shares Program. The shares of phantom stock become payable in cash upon the reporting person's termination of service as an employee of the Issuer. Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 85,000 | $15.45 | $1,313,250.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 11 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,500 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 24,000 | $15.44 | $370,560.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 10 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,500 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 31,500 | $15.43 | $486,045.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 9 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,500 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 34,500 | $15.42 | $531,990.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 8 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,000 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 36,500 | $15.41 | $562,465.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 7 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,500 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 32,000 | $15.40 | $492,800.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 6 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,000 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 14,500 | $15.38 | $223,010.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 5 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 34,000 | $15.37 | $522,580.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 4 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,500 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 5,000 | $15.36 | $76,800.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 3 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,500 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 3,000 | $15.35 | $46,050.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 2 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,500 Read SEC document |
| November 26, 2003 Filed Nov 28, 2003 13:35 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 3,500 | $15.32 | $53,620.00 |
DisclosureSEC source: 0000310158-03-000133 · has294.xml · nonDerivative · entry 1 HASSAN FRED · CIK 0001110744 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,500 Read SEC document |
| November 26, 2003 Filed Dec 2, 2003 01:41 UTC Amendment | Merck & Co., Inc. SGP · Entity 2807 | PurchaseCommon Shares | 85,000 | $15.45 | $1,313,250.00 |
DisclosureSEC source: 0000310158-03-000134 · has298.xml · nonDerivative · entry 11 HASSAN FRED · CIK 0001110744 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,500 F1 · kind: Due to clerical error, the Form 4 for this transaction showed an A transaction code instead of the correct P transaction code. Each transaction was an open market purchase. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.